Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 Nachrichtenquelle: globenewswire | 18.04.2021, 21:05 | 113 | 0 Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 points Improvement in cardiac function for all 7 evaluable patients demonstrated by a decrease in global longitudinal strain (GLS) Emerging Science Oral Presentation today at AAN 2021 DUBLIN, Ireland, April 18, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at the American Academy of Neurology (AAN) 2021 Virtual Annual